聚乙二醇干扰素α‑2b治疗原发性血小板增多症早期起效的影响因素研究OA
Factors influencing early response to peginterferon α‑2b in treatment of essential thrombocythemia
目的 探讨聚乙二醇干扰素α-2b治疗原发性血小板增多症(ET)早期起效的影响因素,探究中药龙柴降血方在早期起效中的作用,为优化ET个体化治疗方案提供依据.方法 回顾性分析接受聚乙二醇干扰素α-2b治疗的ET患者的临床资料,根据起效时间分为快起效组(<5周)和慢起效组(≥5周),分析两组患者一般资料、血常规、基因突变情况、骨髓活检情况以及其他生化指标之间的差异,采用单因素分析和logistic回归分析筛选早期起效的独立影响因素.结果 ①共纳入64例病例,其中快起效组31例(48.44%)、慢起效组33例(51.56%),中位起效时间为[5.0(3.0,6.0)]周.②单因素分析显示,与慢起效组相比,快起效组年龄>50岁的患者、联合使用中药的患者比例更高(P<0.05),血中血小板计数(PLT)、PLT压积(PCT)、淋巴细胞(L)绝对值降低(P<0.05),骨髓巨核细胞数减少(P<0.05).③使用中药[OR=8.637,95%CI(1.774～42.059),P<0.05]、PCT≤0.655%[OR=0.000 4,95%CI(0.000 2～0.210),P<0.05]、巨核细胞数≤70个/低倍视野[OR=0.992,95%CI(0.984～1.000),P<0.05]是聚乙二醇干扰素α-2b治疗ET早期起效的独立影响因素.结论 PCT水平、骨髓巨核细胞数及联合使用中药龙柴降血方是聚乙二醇干扰素α-2b治疗ET早期起效的独立影响因素,中药龙柴降血方作为干预因素,能够影响聚乙二醇干扰素α-2b治疗ET的早期起效.
Objective To investigate the factors influencing early response to peginterferon α-2b in patients with essential thrombocythemia(ET)and to explore the role of Longchai Jiangxue Formula in facilitating the early onset,providing evidence for optimizing individualized ET treatment.Methods Clinical data of ET patients treated with peginterferon α-2b were analyzed retrospectively.Patients were divided into an early-response group(<5 weeks)and a delayed-response group(≥5 weeks)based on the time to response.Differences in baseline demographics,complete blood counts,gene mutations,bone marrow biopsy findings,and other biochemical indices were analyzed between the two groups.Univariate and logistic regression analyses were performed to identify independent factors influencing the early response.Results ①A total of 64 patients were included,with 31 cases(48.44%)in the early-response group and 33 cases(51.56%)in the delayed-response group.The median time to response was[5.0(3.0,6.0)]weeks.② Univariate analysis showed that compared with the delayed-response group,the early-response group had a higher proportion of patients aged>50 years and those receiving traditional Chinese medicine therapy(P<0.05).Meanwhile,the early-response group showed lower peripheral platelet count(PLT),plateletcrit(PCT),absolute lymphocyte count(L),and bone marrow megakaryocyte count(P<0.05).③Logistic regression identified traditional Chinese medicine combination[OR=8.637,95%CI(1.774,42.059),P<0.05],PCT≤0.655%[OR=0.000 4,95%CI(0.000 2,0.210),P<0.05],and megakaryocyte count≤70 per low-power field[OR=0.992,95%CI(0.984,1.000),P<0.05]as independent factors influencing the early response to peginterferon α‐2b in ET.Conclusions PCT levels,bone marrow megakaryocyte counts,and combined use of Longchai Jiangxue Formula are independent factors influencing the early response to peginterferon α-2b in ET.As an active intervention factor,Longchai Jiangxue Formula can influence the early therapeutic response to peginterferon α-2b in treating ET.
牛继聪;孙妍;刘为易;王明镜;吕妍;胡晓梅
北京中医药大学研究生院(北京 100029)||中国中医科学院西苑医院血液科(北京 100091)中国中医科学院西苑医院苏州医院(苏州市中医医院南区)血液科(江苏 苏州 215003)中国中医科学院西苑医院血液科(北京 100091)中国中医科学院西苑医院血液科(北京 100091)中国中医科学院西苑医院血液科(北京 100091)中国中医科学院西苑医院血液科(北京 100091)||中国中医科学院西苑医院苏州医院(苏州市中医医院南区)血液科(江苏 苏州 215003)
原发性血小板增多症聚乙二醇干扰素α-2b龙柴降血方中药起效时间临床研究
essential thrombocythemiapeginterferon α‐2bLongchai Jiangxue FormulaChinese materia medicatime to responseclinical research
《上海中医药杂志》 2026 (10)
62-67,90,7
国家自然科学基金项目(82174360)中国中医科学院科技创新工程重点协同攻关项目(CI2023C027YL)中国中医科学院科技创新工程重大攻关项目(CI2021A01702)
评论